Citi initiated coverage of Acadia Pharmaceuticals (ACAD) with a Buy rating and $33 price target The firm believes Nuplazid and Daybue adoption will continue to increase in the near term. Acadia shares are being over-penalized for Nuplazid sales despite the patent litigation being resolved, the analyst tells investors in a research note.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACAD:
- ACADIA Pharmaceuticals: Hold Rating Amid Pipeline Shifts and Product Focus
- Acadia Pharmaceuticals price target lowered to $29 from $35 at Deutsche Bank
- ACADIA Pharmaceuticals: Growth Potential Despite Setbacks with Promising Pipeline and Core Business Expansion
- Video: Soleno Therapeutics stock rallies on competitor’s failed trial
- Micron reports Q4 beat, Instagram reports 3B MAUs: Morning Buzz